WHO ICTRP trial
Clinical trial study to investigate safety and efficacy of ImmunoSEB and…
CTRI/2020/08/027168 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2020/08/027168 |
|---|---|
| Public title | Clinical trial study to investigate safety and efficacy of ImmunoSEB and ProbioSEB |
| Scientific title | A randomized, open label, 2 Arm, prospective study to investigate the safety and efficacy of the health supplements ImmunoSEB+ProbioSEB CSC3 as supplemental therapy in confirmed mild to moderate COVID-19 patients. |
| Primary sponsor | SRV Hospital |
| Secondary sponsors | SRV Hospital |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | India |
| Conditions | Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere |
| Interventions | Intervention1: ImmunoSEB plus ProbioSEB CSC3: ImmunoSEB Capsule / 500 mg 2 capsule bid and ProbioSEB CSC3 Capsule / 5 billion CFUs 2 Capsule OD for 14 days Control Intervention1: Standard Care: standard care given as per institutional… |
| Registration date | Aug 14, 2020 |
| Target size | 60 |
| Secondary IDs | PROCLIN_COVID-005 ver.1.0 date 09 July 2020 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: